Bioxcel Therapeutics Logo

AI-based Drug Re-innovation

BioXcel Therapeutics, Inc. is a
biopharmaceutical company developing transformative medicines in neuroscience utilizing artificial intelligence.

Innovative Medicine
Backed by the
Power of AI

BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing artificial intelligence, or AI, techniques.

Innovative Medicine
Backed by the Power of AI

BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing artificial intelligence, or AI, techniques.

Our Approach to Drug Development

Latest News

May 09, 2024
BioXcel Therapeutics Reports First Quarter 2024 Financial ResultsVIEW RELEASE
Apr 25, 2024
BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024VIEW RELEASE
Apr 24, 2024
BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual MeetingVIEW RELEASE

Stock Information

BioXcel Therapeutics, Inc.

May 20, 2024 04:00 PM

MARKET/SYMBOL

Nasdaq:

BTAI

PRICE

2.1

CHANGE

0.03 (1.45%)
Scroll to Top

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries. This web site is intended to help healthcare professionals practicing in the US find scientifically balanced, evidence-based information about Bioxcel Therapeutics drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.